$29.25 -0.76 (-2.53%)

Sionna Therapeutics, Inc. Common Stock (SION)

Sionna Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies targeting cell signaling pathways involved in oncology and other diseases. Leveraging advanced scientific research, the company aims to create novel treatments that address unmet medical needs in cancer and related conditions.

🚫 Sionna Therapeutics, Inc. Common Stock does not pay dividends

Company News

Sionna Therapeutics to Participate in Upcoming September Investor Conferences
GlobeNewswire Inc. • Sionna Therapeutics • August 27, 2025

Sionna Therapeutics, a clinical-stage biopharmaceutical company focused on cystic fibrosis treatments, will participate in two upcoming investor conferences in September 2025, presenting their research on CFTR protein function normalization.

Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Benzinga • Globe Newswire • February 10, 2025

Sionna Therapeutics, a clinical-stage biopharmaceutical company, announced the closing of its upsized initial public offering, raising $219.2 million. The company is developing novel medicines to treat cystic fibrosis by normalizing the function of the CFTR protein.